No disease-modifying therapies (DMTs) are approved for nonrelapsing, progressive forms of MS, which comprise the majority of chronic progressive multiple sclerosis (CP-MS) patients. Current treatment relies heavily on off-label use of products approved for the treatment of relapsing forms of MS, or anti-inflammatory agents that are not approved at all for MS. This Unmet Need content provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need in CP-MS. We analyze the commercial opportunities and how emerging therapies may capitalize on these opportunities.

Table of contents

  • Multiple Sclerosis - Unmet Need - Detailed, Expanded Analysis Chronic Progressive Multiple Sclerosis

Author(s): Dr. Ankuri Setia, BDS, PGDHM

Dr. Ankuri Setia is a Biopharma Insight Analyst in the CNS team at Decision Resources Group.

She comes with a work experience of 2 years as Knowledge Management Associate with practice across multiple therapy areas and indications on various functions in secondary research, competitive intelligence and product profiling, market assessment and pipeline analysis, and clinical trials assessment. She earned a Master of Healthcare Management degree from Institute of Health Management Research, a Deemed University.


Related Reports

Multiple Sclerosis - Landscape & Forecast - Disease Landscape & Forecast

The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will c...

View Details

Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis (US) - 2020

Three disease-modifying therapies (DMTs)—EMD Serono’s Mavenclad, Novartis’s Mayzent, and Biogen’s Vumerity—joined the crowded U.S. multiple sclerosis (MS) market just...

View Details

Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis Multiple Sclerosis 2020 – Main Report Dashboard (US)

With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues...

View Details

Multiple Sclerosis - Unmet Need - Detailed, Expanded Analysis - Relapsing Forms Of MS (US/EU)

A growing number of clinically unique disease-modifying therapies (DMTs) have been approved for the treatment of relapsing forms of multiple sclerosis...

View Details